Pulsus Group is glad to announce the 2017 conference in the Hematology series, the 9th International Conference on Clinical and Experimental Hematology. It is going to be held on October 16-17, 2017 at Rome, Italy.
Clinical Hematology 2017 has been designed with many interesting and informative scientific sessions; it includes all possible Clinical and Experimental aspects of Hematology research and runs under the theme of “Breakthroughs and setbacks in Clinical and Experimental Hematology”.
Pulsus Group Inc is a Medical publisher that adheres to stringent peer-review procedure with a view to set an example in promoting standard medical research with integrity. Pulsus Group takes pride in getting the endorsements of prestigious associations and societies like Canadian medical societies. As an ardent supporter of medical publishing, Pulsus Group closely associates with the Canadian and other international medical research associations. It publishes a wide range of medical journals that focus on medical specialties like cardiology, Integrative Medicine, Surgery and Reproductive Medicine. Pulsus group is closely associated with globally renowned academic and research societies like Canadian Society of Plastic Surgeons, Canadian Society for Aesthetic Plastic Surgery, Groupe pour l'Avancementde la Microchirurgie Canada, Canadian Society for Surgery of the Hand.
Track 1: Hematologic Oncology
Hematologic oncology is the branch of medicine concerned with the study, diagnosis, treatment, and prevention of diseases related to blood. Haematology includes the study of etiology. It involves treating diseases that affect the production of blood and its components, such as blood cells, haemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. The laboratory work that goes into the study of blood is frequently performed by a medical technologist or medical laboratory scientist.
Haematologists also conduct studies in oncology and work with oncologists, people who may specialize only in that field instead of both-the medical treatment of cancer. There are various disorders that people are affected by haematology. A few of these different types of blood conditions that are looked at include anemia, hemophilia, general blood clots, bleeding disorders, etc.
Track 2: Blood Transplantation
The umbilical cord is a conduit between the developing embryo or fetus and the placenta. The umbilical vein supplies the fetus with nutrient-rich blood from the placenta The hematopoitic bone marrow transplant, the HSC are removed from a large bone of the donor, typically the pelvis, through a large needle that reaches the centre of the bone. Acute myeloid leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells and the Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.
The Hemostatic is a process which causes bleeding to stop, meaning to keep blood within a damaged blood vessel this is the first stage of wound healing. Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a co-occurrence of three out of five of the following medical conditions, obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low high-density lipoprotein (HDL) levels. Metabolic syndrome increases the risk developing cardiovascular disease and diabetes.
Track 3: Blood Disorders
Hemophilia A is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males. About 70% of the time it is inherited as an X-linked recessive trait, but around 30% of cases arise from spontaneous mutations. Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of haemophilia, rarer than haemophilia A. It is sometimes called Christmas disease, named after Stephen Christmas, the first patient described with this disease.In addition, the first report of its identification was published in the Christmas edition of the British Medical Journal. Hemophilia C is a mild form of haemophilia affecting both sexes. However, it predominantly occurs in Jews of Ashkenazi descent. It is the fourth most common coagulation disorder after von Willebrand's disease and haemophilia A and B.
In USA it is thought to affect 1 in 100,000 of the adult population, making it 10% as common as haemophilia A. Idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenia, primary immune thrombocytopenia,primary immune thrombocytopenic purpura or autoimmune thrombocytopenic purpura, is defined as isolated low platelet count (thrombocytopenia) with normal bone marrow and the absence of other causes of thrombocytopenia Von Willebrand diseases is the most common hereditary coagulation abnormality described in humans. Platelets also called "thrombocytes" are blood cells whose function (along with the coagulation factors) is to stop bleeding by clumping and clogging blood vessel injuries. Platelets have no cell nucleus: Coagulation is highly conserved throughout biology; in all mammals, coagulation involves both a cellular (platelet) and a protein (coagulation factor) component and these are occoured due to genetic blood disorders.
Track 4: Diagnosis in Blood Disorder
Palliative care is a multidisciplinary approach to specialised medical care for people with serious illnesses The spleen, similar in structure to a large lymph node, acts as a blood filter. Anticoagulants (antithrombics) are a class of drugs that work to prevent the coagulation (clotting) of blood. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and renal dialysis equipment. An vena cava filter is a type of vascular filter, a medical device that is implanted by interventional radiologists or vascular surgeons into the inferior vena cava to presumably prevent life-threatening pulmonary emboli is therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. The subspecialty of oncology that focuses on radiotherapy is called radiation oncology.
Translational research is another term for translated research and translational science, Applying knowledge from basic science is a major stumbling block in science, partially due to the compartmentalization within science. Targeted drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others.
Track 5: Hematology
Erythrocytes are also known as red blood cells which carry oxygen to the body and collect carbon dioxide from the body by the use of hemoglobin and its life span of 120 days. along the side the leucocytes helps in protecting the healthy cells because the W.B.C (leucocytes) act as the defending cells in protecting the immune system from the foreign cells. These leucocytes are multipotent cells in bone marrow and there life span is of 3-4 days where the yellow blood cells are called as thrombocytes they are where small and irregular in shape they have life span of 5-9 days they are mostly seen in mammals they help in clotting of blood which are in fibrin form called as thrombosis these lead to heart stroke, blockage of blood in blood mostly in arms and legs. where C.B.C is known as complete blood count is done to know the number of cells in a body these are mainly done by lab technician presently they are been tested by automatic analyzer the high and low amount of cells will lead to many diseases.
Decrease of R.B.C in the body these causes of anemia which leads to weakness, feeling of tired, shortness of breath and person will be noticeably pale. Formation of blood cellular components are called as Hematopoiesis and all the cellular blood components are derived from hematopoiesis stem cells in a healthy individual nearly 1011–1012 new blood cells are produced these help in steady peripheral circulation. If there is a increases of R.B.C in the body these causes polycythemia these can be measured through hematocrit level.
Track 6: Various Aspects of Hematology
Pediatric Haematology and Oncology is an international peer-reviewed medical journal that covers all aspects of pediatrichematology and oncology. The journal covers immunology, pathology, and pharmacology in relation to blood diseases and cancer in children and shows how basic experimental research can contribute to the understanding of clinical problems. Physicians specialized in hematology are known as hematologists or haematologists. Their routine work mainly includes the care and treatment of patients with hematological diseases, although some may also work at the hematology laboratory viewing blood films and bone marrow slides under the microscope, interpreting various hematological test results and blood clotting test results. In some institutions, hematologists also manage the hematology laboratory. Physicians who work in hematology laboratories, and most commonly manage them, are pathologists specialized in the diagnosis of hematological diseases, referred to as hematopathologists or haematopathologists. Experimental Hematology is a peer-reviewed medical journal of hematology, which publishes original research articles and reviews, as well as the abstracts of the annual proceedings of the Society for Hematology and Stem Cells and they should be done under the Hematology guidlines.
Track 7: Blood Based Products
A blood substitute is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another. Thus far, there are no well-accepted oxygen-carrying blood substitutes, which are the typical objective of a red blood cell transfusion; however, there are widely available non-blood volume expanders for cases where only volume restoration is required. These are helping doctors and surgeons avoid the risks of disease transmission and immune suppression, address the chronic blood donor shortage, and address the concerns of Jehovah's Witnesses and others who have religious objections to receiving transfused blood. Pathogen reduction using riboflavin and UV light is a method by which infectious pathogens in blood for transfusion are inactivated by adding riboflavin and irradiating withUV light. This method reduces the infectious levels of disease-causing agents that may be found in donated blood components, while still maintaining good quality blood components for transfusion. This type of approach to increase blood safety is also known as “pathogen inactivation” in the industry. An artificial cell or minimal cell is an engineered particle that mimics one or many functions of a biological cell. The term does not refer to a specific physical entity, but rather to the idea that certain functions or structures of biological cells can be replaced or supplemented with a synthetic entity. Often, artificial cells are biological or polymeric membranes which enclose biologically active materials. As such, nanoparticles, liposomes, polymersomes, microcapsules and a number of other particles have qualified as artificial cells. Manufacturing of semi synthetic products of drugs are known as therapeutic biological products. Anticoagulants (antithrombics) are a class of drugs that work to prevent the coagulation (clotting) of blood. Such substances occur naturally in leeches and blood-sucking insects.
Track 8: Hematology and Nursing
Hematology nurses are specially trained to provide nursing care for patients with blood diseases or disorders. Some of the more commonly-known blood diseases and disorders a hematology nurse may encounter include: leukemia, lymphoma, sickle cell anemia and hemophilia. Hematology nurses initiate a plan of care to manage symptoms that result from such blood problems. Hematology nursing is often closely associated with oncology nursing, and some nurses will help patients with pain management if their cancer is particularly aggressive. Hematology nurses may work with adults only or specialize in working only with children. Their responsibilities include: taking medical histories, performing examinations, starting IVs and working with physicians to diagnose various blood diseases and disorders. Hematology nurses also educate patients and their families on how to live with and manage their blood disease. They may also assist with blood transfusions, blood tests, research and chemotherapy. Advanced practice hematology nurses have some prescriptive authority and can also order diagnostic lab work done.Hematology nurses are specially trained to provide nursing care for patients with blood diseases or disorders. Some of the more commonly-known blood diseases and disorders a hematology nurse may encounter include: leukemia, lymphoma, sickle cell anemia and hemophilia.
Hematology nurses initiate a plan of care to manage symptoms that result from such blood problems. Hematology nursing is often closely associated with oncology nursing, and some nurses will help patients with pain management if their cancer is particularly aggressive. Hematology nurses may work with adults only or specialize in working only with children. Their responsibilities include: taking medical histories, performing examinations, starting IVs and working with physicians to diagnose various blood diseases and disorders. Hematology nurses also educate patients and their families on how to live with and manage their blood disease. They may also assist with blood transfusions, blood tests, research and chemotherapy. Advanced practice hematology nurses have some prescriptive authority and can also order diagnostic lab work done.
Track 9: Hematology and Pharma industry
The global market for Hematologic drugs is predicted to grow twice as fast as that of other pharmaceuticals over the next five years. Top companies in the list includes Janssen biotech, Takeda oncology, Boehringer ingelheim, Roche, Novartis, Celgene, Johnson & Johnson, Bristol-Myers Squibb, Lilly, Takeda, AstraZeneca, Merck & Co., Amgen, Pfizer, Astellas, Bayer, Otsuka, Sanofi, Merck KGaA, Eisai, AbbVie, Pharmacyclics, Incyte
The Pharma industry embraces hematology in producing various Biological Drugs and Generic Drugs with Increasing Investments, Healthcare Expenditures and growth in Cancer Pharmaceutical Companies.
Track 10: Hematological Disorders
Lymphatic leukemia which effect the white blood cells(w.b.c) they are closely related to the lymphomas and some of them are unitary diseases which related to the adult T cells leukemia these come under the lymphoproliferative disorders. Mostly they involve in the B-cell sub type lymphocytes. The myeloid leukemia is preferred to the granulocyte precursor in the bone marrow and spinal cord and these arises the abnormal growth in the blood from tissues in the bone marrow. They are mainly related to the hematopoietic cells and these sub title into acute and chronic lymphoblastic leukemia. The acute leukemia is that rapidly producing immature blood cells as they are bulk number of cells healthy cells are not produced in bone marrow due this spill over the blood stream which spread to other body parts. Whereas in chronic leukemia highly built of matured cells are formed but still abnormal white cells are formed these cannot be treated immediately mostly seen in older people.
The cancer which originates from white blood cells are called as lymphoma and this disorder is mainly seen in Hodgkin lymphoma these diseases are treated by radiation and chemotherapy, or hematopoietic stem cell transplantation. The cancer which starts with in the cell are called as Non Hodgkin lymphocytes and these lymphocytes are of lymph nodes. The bone marrow which develops too many white blood cells leads to multiple myleoma. The further details on malignance are been discussed in Hematology conference.
Track 11: Hematology Diagnosis
Diagnosis in Hematology disorders and diseases is a very difficult task and requires an expert and sophisticated technology to accomplish it. The recent developments in the technology with the diagnostics has driven the hematology diagnosis a distinguishable extent forward to meet the needs of the present day disease diagnosis and treatment.
Various aspects comprise the diagnosis in hematology study. Of them, key objects such as Hematology Blood tests and Hematology pathophysiology play an undividable role in the hematology diagnosis.
Track 12: New Drugs in Haematology
The development of antibiotic resistance in particular stems from the drugs targeting only specific bacterial molecules. Because the drug is so specific, any mutation in these molecules will interfere with or negate its destructive effect, resulting in antibiotic resistance. Known as Drug delivery Conditions treated with combination therapy include tuberculosis, leprosy, cancer, malaria, and HIV/AIDS. One major benefit of combination therapies is that they reduce development of drug resistance, since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. Artemisinin-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment. Drug Induced Blood Disorders causes of sickle cell anemia,pale skin non steroids anti-inflammatory drugs which causes ulcers Using drug repositioning, pharmaceutical companies have achieved a number successes, for example Pfizer's Viagra in erectile dysfunction and Celgene's thalidomide in severe erythema nodosum leprosum. Smaller companies, including Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and SOM Biotech are also performing drug repositioning on a systematic basis. These companies use a combination of approaches including in silico biology and in vivo/in vitro experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.
Track 13: Hematology and Immunology
Blood groups are of ABO type and but at present the Rh blood grouping of 50 well defined antigens in which 5 are more important they are D,C,c,E and e and Rh factors are of Rh positive and Rh negative which refers to the D-antigen. These D-antigen helps in prevention of erythroblast fetalis lacking of Rh antigen it defined as negative and presences of Rh antigen in blood leads to positive these leads to rh incompatibility. The prevention treatment of diseases related to the blood is called as the Hematology. The hematologists conduct works on cancer to. The disorder of immune system leading to hypersensitivity is called as Clinical Immunology and the abnormal growth of an infection are known as Inflammation and the arise of an abnormal immune response to the body or an immune suppression are known as Auto immune disorder. The stem cell therapy is used to treat or prevent a disease or a condition mostly Bone marrow stem cell therapy is seen and recently umbilical cord therapy Stem cell transplantation strategies remains a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases.
Track 14: Hematology: Case Reports
A case report is an enlarged report of all the details of a disease or of a disorder especially made for an individual patient usually logged in medical field. Case reports might realize a demographic profile of the patient, but stereotypically reference any unusual or unique incidences.
In this hematology based conference, various special cases where no treatment was discovered or a special case which might lead the insights into the hematology research are discussed.
Track 15: Entrepreneurs Investment Meet
Several biotech and pharmaceutical industries are arising every day. Each of them partially or completely relate to the hematology. Many research teams are formed all over the world to work on hematology and clinical and experimental aspects of it. Large scale production of diagnostics and drugs is fashioned now to meet the needs of the increasing demand as the expanded research field suggests.
Pulsus Group is glad to announce the 2017 conference in the Hematology series, the 9th International Conference on Clinical and Experimental Hematology. It is going to be held on October 16-17, 2017 at Rome, Italy.
Clinical Hematology 2017 will be organized around the theme “Breakthroughs and setbacks in Clinical and Experimental Hematology”.
Clinical Hematology 2017 is comprised of many interactive scientific sessions on different types of Blood disorders as well as various diagnostic and therapeutic advancements in this field. It is an initiative to unite the diverse research and business communities working in this field under a one roof to explore every single aspect of Hematology and Blood Diseases. Clinical Hematology 2017 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it in Hematology conferences.
According to market study, market value of Hematology at present is $15.13 billion. A major part of research is going on at the top Universities across the globe, on Hematology conference and the grants allotted for this research field is around $10.54 billion. Many companies are associated with the blood testing equipment along with various diagnostic instruments, hematologic drugs and other therapeutics, the revenue generated is around $21.1 billion on average by this companies. Besides this various societies and research labs are also associated in this research field.
Clinical Hematology 2017 will provide an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings.
Why to attend?
Clinical Hematology 2017 will provide a stimulating scientific environment and a platform for the participants to exchange ideas, establish research collaboration and networking by attending the Hematology conferences. It will be amazing opportunity for the attendees to explore the beautiful city with gaining knowledge, sure to raise insights, conflate present with future and cogitate on ideas and reality in Hematology meetings. To fight against these hard to cure blood diseases, Clinical Hematology 2017 has taken this initiative to explore every aspects of Hematology research.
Hematology is a branch of biology that includes various research areas such as pathology, internal medicine, clinical laboratory, physiology, immunology and pediatrics. This conference will witness a collection of various arenas in Hematology and as it involves a vast range of medical streams within it. This conference will be an excellent platform for interdisciplinary interactions, to exchange and share knowledge under a single roof.
The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Clinical Hematology 2017, where you will be sure to have a meaningful experience with scholars from around the world.
Importance & Scope:
Clinical Hematology 2017 offers the best platform for the experts, researchers, students and business delegates with its well organized scientific program covering every minute detail about the clinical and experimental aspects on hematology and blood diseases, from the basic causes behind blood diseases to the latest trends in diagnostic and treatment of blood diseases. This international event is an effort to find a weapon against chronic disorders like blood cancer, Sickle cell anemia, hemophilia, lymphoma and myeloma and to discuss the role of Immunoglobulin in blood, antibody and antigen reactions, the red blood cell and the immunological properties of blood which gives a better insight about the associated causes and disease portfolio.
Pulsus Group Inc welcomes all the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of the esteemed Clinical Hematology 2017. Advanced Diagnostic and therapeutic equipment along with the novel drugs for the blood diseases are an integral part of the Hematology research, hence it will be an excellent amalgamation of academia and industry as it involves every aspects of empirical and conceptual thinking in exploring new dimensions in this field. It is open to all types of research methodologies both from academia and industry.
Conference Highlights :
Glance at Market of Hematology :
According to market study, the total market value of Hematology at present is $15.13 billion. The hematology products segment holds the largest share of the hematology market in 2016. The market value is analysed by 2 segments, namely, hematology reagents and hematology instruments. These two segments had a positive growth till 2013, with a total market value of $4.3 billion, covering $0.6 billion for instruments and $3.6 billion for reagents, and growing at a CAGR of 7.3%. The global market of hematology instruments and reagents, by 2019, is expected to reach $3.13 billion, at CAGR of 5.2% from 2014 to 2019.
The global hematology market is divided into hematology products & services. Hematology products market has been segmented into instruments and consumables. The hematology instruments market is further segmented into analyzers and slide strainers/makers. Whereas, the hematology consumables market has been classified into three major segments namely; regents, stains, and controls and calibrators. Furthermore, based on the end-users, the global hematology market has been segmented into commercial organizations, stand-alone hospitals, research institutes, and clinical testing labs.
The Centers for Medicare & Medicaid Services (CMS) has estimated that the healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2018, at a CAGR of 6.8% for the same period. Europe holds the second largest market. Similarly, in emerging countries, the growing awareness and an increasing middle-class population, with more disposable incomes to spend on healthcare, are the driving factors for the growth of coagulation market.
It is also expected to grow at the highest growth rate by next five years, owing to the increasing development of new hematology reagents. In addition, based on the end-users, the global hematology market has been segmented into commercial organizations, stand-alone hospitals, research institutes, and clinical testing labs. The clinical testing labs hold the largest share of the hematology market in 2017.
A major part of research is going on at the top Universities across the globe, the grants allotted for this research field is around $10.54 billion. Many companies are associated with the blood testing equipment along with various diagnostic instruments, hematologic drugs and other therapeutics, the revenue generated is around $21.1 billion on average by this companies. Besides this various societies and research labs are also associated in this research field.